Skip to main content
SpringerLink
Log in

Besitzt R-(—)-Deprenyl möglicherweise eine Schutzwirkung beim Morbus Parkinson?

  • Conference paper
Morbus Parkinson Selegilin (R-(—)-Deprenyl); Movergan®

Part of the book series: Journal of Neural Transmission. Supplementa ((volume 25))

  • 25 Accesses

Zusammenfassung

Der selektive Monoaminoxidase-Hemmer (MAO-B-Hemmer) L-Deprenyl (Eldepryl®, Jumex®, Movergan®, Selegilin) hat sich bei der Behandlung des Morbus Parkinson als Adjuvans bewährt. Seit kurzem wird erwogen, daß Deprenyl möglicherweise den Verlauf des Morbus Parkinson durch eine Verlangsamung der Progression wirksam beeinflussen könnte. Diese „neue therapeutische Strategie“ beruht auf unterschiedlichen Beweisführungen, die in 3 Kategorien einzuordnen sind: Theoretisch, experimentell und empirisch. Einzelheiten einer noch laufenden doppelblinden, Placebo-kontrollierten, prospektiven klinischen Studie einer Therapie mit Deprenyl bei Patienten mit unbehandeltem Morbus Parkinson in der Frühphase werden hier vorgelegt. Diese Studie dient der direkten Prüfung der Hypothese, daß Deprenyl die natürliche Entwicklung dieser Krankheit günstig beeinflussen könnte. Durch eine genaue Prüfung dieser neuen Hypothese könnten sich wesentliche Auswirkungen auf die gegenwärtigen Behandlungskonzepte und die therapeutische Beherrschung des Morbus Parkinson ergeben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Baldessarini RJ (1980) Drugs and the treatment of psychiatric disorders. In: Gilman AG, Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics, 6th edn. Macmillan, New York, chap 19, pp 427–430.

    Google Scholar 

  • Ballard P, Tetrud JW, Langston JW (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP): seven cases. Neurology 35: 949–956.

    Article  PubMed  CAS  Google Scholar 

  • Barbeau A (1960) Biochemistry of Parkinson’s disease. Excerpta Medica Int Cong Series 3: 152–153.

    Google Scholar 

  • Barbeau A (1984) Etiology of Parkinson’s disease: a research strategy. Can J Neurol Sci 11: 24–28.

    PubMed  CAS  Google Scholar 

  • Birkmayer W (1983) Deprenyl (selegiline) in the treatment of Parkinson’s disease. Acta Neurol Scand 68 [Suppl] 95: 103–106.

    Article  Google Scholar 

  • Birkmayer W, Hornykiewicz O (1961) Der L-3-dioxyphenylalanin (L-DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787–788.

    PubMed  CAS  Google Scholar 

  • Birkmayer W, Riederer P, Ambrozi L, Youdim MBH (1977) Implications of combined treatment with Madopar and L-deprenyl in Parkinson’s disease. Lancet ii: 439–443.

    Article  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH (1983) (—)Deprenyl leads to prolongation of L-dopa efficacy in Parkinson’s disease. Mod Probl Pharmaco-psychiatry 19: 170–176.

    CAS  Google Scholar 

  • Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64: 113–127.

    Article  PubMed  CAS  Google Scholar 

  • Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz D, Kopin IJ (1983) A primate model of Parkinson’s disease: Selective destruction of substantia nigra, pars compacta dopaminergic neurons by N-methyl-4-phenyl-1-2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550.

    Article  PubMed  CAS  Google Scholar 

  • Burton K, Calne DB (1984) Pharmacology of Parkinson’s disease. In: Jankovic J (ed) Neurologic clinics—movement disorders. WB Saunders, Philadelphia, pp 461–472.

    Google Scholar 

  • Calne DB, Langston JW (1983) Aetiology of Parkinson’s disease. Lancet ii: 1457–1459.

    Article  Google Scholar 

  • Calne DB, Langston JW, Martin WRW, Stoessel AJ, Ruth TJ, Adam MJ, Pate BD, Schulzer M (1985) Positron emission tomography after MPTP: Observations relating to the cause of Parkinson’s disease. Nature 317: 246–248.

    Article  PubMed  CAS  Google Scholar 

  • Carlsson A (1959) The occurrence, distribution and physiologic role of catecholamines in the nervous system. Symposium on Catecholamines, Bethesda, MD, October 16-18, 1958. Pharmacol Rev 11: 490.

    PubMed  CAS  Google Scholar 

  • Chiba K, Trevor AJ, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578.

    Article  PubMed  CAS  Google Scholar 

  • Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, Castagnoli N Jr (1985) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Drug Metab Dispos 13: 342–347.

    PubMed  CAS  Google Scholar 

  • Cohen G (1983) The pathobiology of Parkinson’s disease: Biochemical aspects of dopamine neuron senescence. J Neural Transm [Suppl] 19: 89–103.

    CAS  Google Scholar 

  • Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1985) Pargyline and deprenyl prevent the toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur J Pharmacol 106: 209–210.

    Article  Google Scholar 

  • Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism-chronic treatment with L-dopa. N Engl J Med 280: 337–345.

    Article  PubMed  CAS  Google Scholar 

  • Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249–254.

    Article  PubMed  CAS  Google Scholar 

  • Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des Extrapyramidalen Systems. Wien Klin Wochenschr 72: 1236–1239.

    Google Scholar 

  • Elsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stern GM, Kumar P (1978) Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38.

    Article  PubMed  CAS  Google Scholar 

  • Fahn S, Elton RL, Members of the UPDRS development committee (1987) Unified Parkinson’s disease, rating scale. In: Fahn S, Marsden CD, Calne DB, Lieberman A (eds) MacMillan health care information, Florham Park, NJ. Recent developments in Parkinson’s disease, vol 2.

    Google Scholar 

  • Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol 20: 449–455.

    Article  PubMed  CAS  Google Scholar 

  • Hallman H, Olsen L, Jonsson G (1984) Neurotoxicity of the meperidine analog N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. Eur J Pharmacol 97: 133–136.

    Article  PubMed  CAS  Google Scholar 

  • Heikkila RE, Manzino L, Duvoisin RC, Cabbat FS (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidase inhibitors. Nature 311: 467–469.

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MMM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442.

    Article  PubMed  CAS  Google Scholar 

  • Javitch JA, Snyder SH (1985) Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin MPTP. Eur J Pharmacol 106: 455–456.

    Article  Google Scholar 

  • Jenner P, Rupniak NH, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism in the common marmoset. Neurosci Lett 50: 85–90.

    Article  PubMed  CAS  Google Scholar 

  • Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–1297.

    Article  PubMed  CAS  Google Scholar 

  • Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 68 [Suppl] 95: 57–80.

    Article  Google Scholar 

  • Knoll J, Ecery Z, Kelemen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpro-pinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155: 154.

    PubMed  CAS  Google Scholar 

  • Langston JW, Ballard P (1984) Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson’s disease. Can J Neurol Sci 11: 160–165.

    PubMed  CAS  Google Scholar 

  • Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980.

    Article  PubMed  CAS  Google Scholar 

  • Langston JW, Forno LS, Rebert CS, Irwin I (1984 a) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292: 390–394.

    Article  PubMed  CAS  Google Scholar 

  • Langston JW, Irwin I, Langston EB, Forno LS (1984 b) Pargyline prevents MPTP-induced parkinsonism in primates. Science 225: 1480–1482.

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, Youdim MBH (1977) Deprenyl in Parkinson’s disease. Lancet i: 791–795.

    Article  Google Scholar 

  • Lewin R (1985) Clinical trial for Parkinson’s disease? Science 230: 527–528.

    Article  PubMed  CAS  Google Scholar 

  • Lewin R (1986) Age factors loom in parkinsonian research. Science 234: 1200–1201.

    Article  PubMed  CAS  Google Scholar 

  • Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA (1984) Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311: 464–467.

    Article  PubMed  CAS  Google Scholar 

  • McGeer PL, McGeer EG, Suzuki JS (1977) Aging and extrapyramidal function. Arch Neurol 34: 33–35.

    Article  PubMed  CAS  Google Scholar 

  • Montgomery GK (1984) Parkinson’s disease and the Columbia scale. Neurology 34: 5578–5580.

    Article  Google Scholar 

  • Nandy K (1983) Aging neurons and pharmacological agents. In: Cervos-Navarro J, Sarkander HI (eds) Brain aging: neuropathology and neuropharmacology. Raven Press, New York (Ageing, vol 21, pp 410–413).

    Google Scholar 

  • Ohye C, Hirai T, Miyazaki M, Shibazaki T, Nakajima H (1981) Vim thalamotomy for the treatment of various kinds of tremor. Appl Neurophysiol 45: 275–280.

    Google Scholar 

  • Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. E & S Livingstone, Edinburgh, pp 152–157.

    Google Scholar 

  • Stern GM, Lees AJ, Sandler M (1978) Recent observations on the clinical pharmacology of (—)deprenyl. J Neural Transm 43: 245–252.

    Article  PubMed  CAS  Google Scholar 

  • Tetrud JW, Langston JW (1986) Early parkinsonism in humans due to MPTP exposure. Neurology 36 (Suppl 1): 308.

    Google Scholar 

  • Wallace RA, Boldry R, Schmittgen T, Millder D, Uretsky N (1984) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on monoamine neurotransmitters in mouse brain and heart. Life Sci 35: 285–291.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Medical Research, 2260 Clove Drive, San José, Kalifornien, 95128, USA

    Dr. J. W. Tetrud & J. W. Langston

Authors
  1. Dr. J. W. Tetrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Langston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. St. Josef-Hospital, Bochum, Bundesrepublik Deutschland

    Horst Przuntek

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Wien

About this paper

Cite this paper

Tetrud, J.W., Langston, J.W. (1988). Besitzt R-(—)-Deprenyl möglicherweise eine Schutzwirkung beim Morbus Parkinson?. In: Riederer, P., Przuntek, H. (eds) Morbus Parkinson Selegilin (R-(—)-Deprenyl); Movergan®. Journal of Neural Transmission. Supplementa, vol 25. Springer, Vienna. https://doi.org/10.1007/978-3-7091-2287-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-2287-7_7

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-82032-2

  • Online ISBN: 978-3-7091-2287-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation